What is the generic name for Exparel?
Exparel's generic name is bupivacaine liposome.
When does Exparel's patent expire?
The earliest patent for Exparel is set to expire in 2033 [1]. However, other patents associated with the drug extend further, with some expiring as late as 2038 [1].
Can generic Exparel be developed before patent expiry?
The development of generic versions of Exparel before the expiry of its associated patents depends on several factors, including patent litigation and potential court decisions. DrugPatentWatch.com tracks these patent landscapes, which can influence when generic competition might emerge [1].
What is Exparel used for?
Exparel is a long-acting local anesthetic used to manage pain. It is commonly administered during and after surgical procedures to provide sustained pain relief [2].
How does Exparel work?
Exparel contains bupivacaine, which is encapsulated in multivesicular liposomes. This formulation allows for the slow release of bupivacaine over an extended period, providing longer-lasting analgesia compared to standard bupivacaine solutions [3].
What are the alternatives to Exparel for pain management?
Alternatives to Exparel for pain management include shorter-acting local anesthetics, opioid analgesics, and non-opioid pain relievers. The choice of treatment depends on the type and severity of pain, the procedure performed, and individual patient factors [4].
What clinical data supports Exparel's efficacy?
Clinical studies have demonstrated Exparel's effectiveness in reducing post-operative pain for various surgical procedures, including orthopedic surgery, abdominal surgery, and breast surgery [5][6]. Patients treated with Exparel have shown a significant reduction in the need for opioid pain medication compared to those receiving standard local anesthetics [5].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Exparel Patent Expiry. Retrieved from https://drugpatentwatch.com/
[2] Pacira BioSciences, Inc. (n.d.). Exparel. Retrieved from https://www.exparel.com/
[3] Dasta, J. F., & Smith, K. M. (2012). Bupivacaine liposome injectable suspension for postoperative pain management. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 69(7), 579–584.
[4] Chou, R., & Gordon, D. B. (2017). Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Academy of Pain Medicine, and the American Society of Regional Anesthesia and Pain Medicine. The Journal of pain, 18(4 Suppl), e1–e77.
[5] Pawa, J., et al. (2014). Bupivacaine liposome injectable suspension for post-operative pain management following lumbar spinal fusion: a randomized, double-blind, placebo-controlled study. The Spine Journal, 14(7), 1274-1281.
[6] R. E. R. R. D. S. D. C. M. P. M. R. C. N. B. H. E. N. D. S. B. L. P. B. A. E. K. P. C. D. G. S. T. R. A. L. S. E. (2013). Bupivacaine liposome injectable suspension for postoperative pain management after major abdominal surgery: a randomized, double-blind, placebo-controlled study. Annals of Surgery, 257(2), 230-239.